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Abstract: Chlorpromazine was synthesized in December 1951 in the laboratories of 
Rhône-Poiulenc, and became available on prescription in France in November 1952. Its 
effectiveness was reﬂ  ected in the transformation of disturbed wards; its commercial success 
stimulated the development of other psychotropic drugs. Recognition of chemical mediation 
at the site of the synapse, followed by the introduction of the spectrophotoﬂ  uorimeter ﬁ  rst, and 
receptor assays subsequently, led to the demonstration that chlorpromazine blocks dopamine 
receptors. Treatment with chlorpromazine focused attention on the heterogeneity of schizophre-
nia in terms of responsiveness to treatment. By the mid-1980s there was sufﬁ  cient evidence to 
believe that resolving this heterogeneity is a prerequisite for developing more effective treat-
ments. Chlorpromazine was instrumental in the development of neuropsychopharmacology, a 
new discipline dedicated to the study of mental pathology with the employment of centrally 
acting drugs.
Keywords: chlorpromazine, history, neuropsychopharmacology, pharmacotherapy, psychiatry, 
schizophrenia.
Introduction
The word “psychopharmacology” was ﬁ  rst used in 1920 by David Macht, an American 
pharmacologist, in the title of his paper describing the effects of the antipyretics, 
quinine and acetylsalicylic acid, on neuromuscular coordination tests (Macht 1920). 
Yet, until the 1950s there was no such scientiﬁ  c discipline as psychopharmacology 
and there was no effective drug therapy for mental illness. In 1952, chlorpromazine 
(CPZ) appeared on the psychiatric scene in Paris. It was more effective than any of 
the old drugs, including morphine and scopolamine (hyoscine) combinations, for 
controlling excitement and agitation, and it could relieve also psychotic symptoms, 
such as delusions and hallucinations.
Although the psychiatric establishment received CPZ incredulously, for psychia-
trists working on the front line it was a miracle drug. Its effectiveness was reﬂ  ected in 
the transformation of disturbed wards and psychiatric service. Its commercial success 
stimulated the development of other psychotropic drugs.
Today, more than 50 years later, psychopharmacology is an established discipline 
and we have several effective drugs for the treatment of a wide variety of psychiatric 
disorders (Ban et al 1998).
From synthesis to introduction
Chlorpromazine was synthesized on December 11, 1951 by Paul Charpentier, in the 
laboratories of Rhône-Poulenc, a French pharmaceutical company, and released for 
clinical investigation in May 1952 as a possible potentiator of general anesthesia 
(Charpentier et al 1952).
The potential use of CPZ in psychiatry was ﬁ  rst recognized by Henri Laborit 
(1952), a surgeon and physiologist in the French army, in the course of his research 
with artiﬁ  cial hibernation in the prevention of surgical shock. In collaboration with Neuropsychiatric Disease and Treatment 2007:3(4) 496
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Huguenard and Alluaume, he employed the drug as an 
adjunct to surgical anesthetics (“anesthetic cocktail,” “lytic 
cocktail”) because of its body temperature lowering effect. 
He found that CPZ, in the dosage of 50 to 100 mg given 
intravenously, produced disinterest without loss of con-
sciousness and with only a slight tendency to sleep. His ﬁ  rst 
paper on CPZ was published in the February 13th issue of 
La Presse Médicale in 1952 with the title “A new vegetative 
(autonomic) stabilizer” (Laborit et al 1952).
Since cooling with water had been used in France for 
controlling agitation (Burger 1976), Laborit was able to 
persuade Hamon, Paraire and Velluz at the neuropsychiatric 
service of Val de Grâce, the military hospital in Paris, to 
try CPZ in the treatment of one of their patients (Caldwell 
1970). Jacques Lh., a 24-year-old severely agitated psychotic 
(manic) male was the ﬁ  rst psychiatric patient to receive CPZ; 
he was administered 50 mg of the drug, intravenously, at 10 
am, on January 19, 1952. The calming effect of CPZ was im-
mediate but since it lasted only a few hours several treatments 
were required before the patient’s agitation was controlled. 
Repeated administration of the drug caused venous irritation 
and perivenous inﬁ  ltration. Hence, on several occasions 
barbiturates and electroshock were substituted for CPZ. 
Nonetheless, after 20 days of treatment, with a total of 855 mg 
of CPZ, the patient was ready “to resume normal life.” The 
effects of CPZ on Jacques Lh. were reported on February 22, 
1952 by Colonel Paraire, at a meeting of the Société Médico-
Psychologique in Paris, and, based on this presentation, the 
ﬁ  rst paper on CPZ in psychiatry was published in the March 
1952 issue of the Annales Médico-psychologiques, the 
ofﬁ  cial journal of the Society (Hamon et al 1952).
Clinical investigations with CPZ at Saint-Anne’s 
hospital – at Pierre Deniker’s service in Jean Delay’s depart-
ment – in Paris began on March 24, 1952 (Caldwell 1970). 
Since it was believed that the drug worked by inducing “ar-
tiﬁ  cial hibernation,” ice packs were used to enhance “cool-
ing.” It did not take long to recognize that “cooling” did not 
contribute to the drug’s therapeutic effect (Thuillier 1999). 
In most patients CPZ alone, in the daily dosage of 75 mg, 
was sufﬁ  cient for controlling behavior. Early ﬁ  ndings with 
CPZ at Saint-Anne were presented on May 25, 1952, at the 
centennial meeting of the Société Médico-Psychologique. 
(Delay et al 1952a). The six publications of Delay and 
Deniker during the six months that followed (Delay and 
Deniker 1952a, 1952b, 1952c; Delay et al 1952a, 1952b, 
1952c), set the stage for the introduction of CPZ in psychiatry 
(Olie 2004). Other publications in 1952 included a report by 
Follin (1952), on the successful treatment of an aggressive 
paranoiac patient with CPZ at Montauban mental hospital in 
France (Caldwell 1970); an article by Rigotti (1952), on 20 
psychiatric patients treated with CPZ in Padua, Italy; and a 
paper by Arnold, Hilt and Solma (1952), on the use of CPZ 
in psychiatry in Vienna, Austria.
CPZ became available on prescription in France, under the 
proprietary name of Largactil, ie, large in action, in November 
1952 (Caldwell 1970). The proprietary name was chosen to re-
ﬂ  ect the diversity of pharmacological actions and potential clini-
cal indications of the drug (Courvoisier et al 1953; Burger 1976; 
Thuillier 2000). Subsequently, within a short period of three 
years, from 1953 to 1955, CPZ treatment in psychiatry spread 
around the world. By the end of 1955 there were reports on the 
effects of CPZ in psychiatric patients from Switzerland (Staehelin 
and Kielholz 1953; Staehelin 1954); England (Anton-Stephens 
1954; Elkes and Elkes 1954); Canada (Lehmann 1954; Lehmann 
and Hanrahan 1954); Germany (Bente and Itil 1954); Hungary 
(Kardos and Pertorini 1954); Latin America (Saly y Rosas et al 
1954), United States (Winkelman 1954); Australia (Webb 1955); 
and the USSR (Tarasov 1955). Heinz Lehmann, a German born 
Canadian psychiatrist at the Verdun Protestant Hospital in Mon-
treal, was ﬁ  rst to suggest that CPZ selectively inhibits affective 
drive (Lehmann 1954). His paper, co-authored by Hanrahan and 
published in the Archives of Neurology and Psychiatry (USA), 
had a major impact on the introduction of CPZ in North America 
(Lehmann and Hanrahan 1954).
The ﬁ  rst international colloquium on the therapeutic uses 
of CPZ in psychiatry was held at Saint-Anne’s Hospital in 
Paris, in October 1955 (Hollister 1994; Thuillier 1999) with 
257 participants from 19 countries (Austria, Belgium, Brazil, 
Canada, Cuba, France, Germany, Great Britain, Holland, 
Luxembourg, Peru, Portugal, Spain, Sweden, Switzerland, 
Turkey, United Kingdom, United States and Venezu-
ela). Two years later, in 1957, the importance of CPZ was 
recognized by the scientiﬁ  c community with the presenta-
tion of the American public health association’s prestigious 
Albert Lasker Award to the three key players in the clinical 
development of the drug: Henri Laborit, for using CPZ as a 
therapeutic agent ﬁ  rst and recognizing its potential for psy-
chiatry; Pierre Deniker, for his leading role in introducing 
CPZ into psychiatry and demonstrating its inﬂ  uence on the 
clinical course of psychosis; and Heinz Lehmann, for bring-
ing the full practical signiﬁ  cance of CPZ to the attention of 
the medical community (Ban 1994).
Early pharmacology
The pharmacological bridge from “antihistamines” to 
“antipsychotics” was provided by a test that could detect Neuropsychiatric Disease and Treatment 2007:3(4) 497
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the central effect of drugs by the increase in time required 
for trained rats to climb a vertical rope for food (Winter 
and Flataker 1951). It was adopted by Simone Courvoisier, 
in the laboratories of Rhône-Poulenc, for measuring the 
central effects of phenothiazines, and used later in com-
bination with other behavioral indicators – such as reduc-
tion of spontaneous motor activity, induction of cataleptic 
immobility, antagonism of apomorphine-induced vomiting, 
inhibition of intracranial self-stimulation – in the pre-clinical 
screening for drugs with a similar therapeutic proﬁ  le to CPZ 
(Courvoisier et al 1953). Leonard Cook, in the pharmaco-
logical laboratories of Smith, Kline & French in the United 
States, was ﬁ  rst to develop a behavioral pharmacological 
test that distinguished CPZ from the barbiturates and other 
old sedatives. It established that CPZ was different from 
barbiturates because it selectively blocked the conditioned 
(behavioral-) avoidance response and left the unconditional 
(escape-) motor reﬂ  ex unaffected (Cook 2004a, 2004b). 
Employment of Cook’s test in the screening for CPZ-like 
compounds led during the late 1950s to a steadily increasing 
number of antipsychotic drugs.
From CPZ to other antipsychotics
The rapidly growing number of antipsychotics was reﬂ  ected 
in the presentations made at the first congress of the 
Collegium Internationale Neuro-Psychopharmacologicum 
(CINP) in Rome, Italy, in 1958. Frank Ayd, an American 
psychiatrist from Baltimore, Maryland, reported on clinical 
ﬁ  ndings of 25 patients, and Hippius and Selbach from Berlin, 
Germany, reported on clinical ﬁ  ndings of 12 patients (Ayd 
1959; Hippius and Selbach 1959). By emphasizing that the 
clinical use of these drugs should be based on the relationship 
between their therapeutic efﬁ  cacy and somatic side effects 
without any theoretical preconception, Hanns Hippius opened 
the path for a development that led from CPZ to clozapine 
(Hippius 2004). It was also at the Rome Congress that Pierre 
Lambert from Lyon, France, ﬁ  rst presented the classiﬁ  cation 
of the Comité Lyonnaise, in which antipsychotic phenothi-
azines were divided into sedative, chlorpromazine-type of 
drugs, which are less potent on a mg per kg basis, producing 
drowsiness and lassitude with relatively few extrapyramidal 
signs (EPS), and incisive, prochlorperazine-type of drugs, 
which are more potent on a mg per kg basis and produce 
ataraxy without drowsiness but with frequent and marked 
EPS (Lambert et al 1959). In 1960, at the 2nd CINP Congress 
in Basel, Switzerland, confronting the commonly held belief 
that incisive neuroleptics are also more effective than sedative 
neuroleptics in the treatment of schizophrenia, Fritz Freyhan, 
a German born American psychiatrist argued that there is no 
difference in therapeutic efﬁ  cacy between the two types of 
drugs (Freyhan 1961).
Impact on neuropharmacology
Simultaneously with the development of CPZ there was a 
shift in understanding of the nature of synaptic transmission 
from a purely electrical to a chemically-mediated event; 
and by the end of the 1950s, six neurotransmitters were 
identified in the central nervous system: acetylcholine, 
dopamine, γ-aminobutyric acid, norepinephrine, serotonin, 
and substance P (Ban 2001). Recognition of chemical media-
tion at the site of the synapse, coupled with the introduction 
of the spectrophotoﬂ  uorimeter (Bowman et al 1955), an 
instrument that allowed the chemical analysis of compounds 
that occur in small amounts in the brain, such as the mono-
amines and their metabolites, triggered the development 
of neuropharmacology in the mid-1950s (Carlsson 1998, 
2004). There were high expectations that CPZ combined 
with spectrophotoﬂ  uorimetry would provide a royal road to 
the understanding of the pathophysiology of schizophrenia. 
It was also hoped that there would be feedback from clinical 
psychopharmacologists to neuropharmacologists, that would 
help to develop clinically more selective and thereby more 
effective pharmacological treatments (Ban 1999).
In 1955, Laszlo Gyermek, a Hungarian born pharmacolo-
gist, was ﬁ  rst to report on the potent antiserotonin effects 
of CPZ (Gyermek 1955). One year later he demonstrated 
a relationship between the sedative and the antiserotonin 
effects of phenothiazines (Gyermek, Lázár and Csák 1956). 
These ﬁ  ndings were contrary to expectations given that in 
1954, prior to Gyermek’s report, LSD25, a psychotomimetic 
substance, was found to have potent antiserotonin effects 
(Woolley and Shaw 1954). Nonetheless, until the early 1960s, 
antiserotonin effects were perceived as integral part of the 
mode of action of antipsychotic dugs.
In the mid-1960s Carlsson and Lindqvist (1963) found 
that the administration of CPZ and haloperidol, the ﬁ  rst 
butyrophenone neuroleptic, stimulated the turnover of cat-
echolamines in the brain of the mice. They attributed their 
ﬁ  ndings to a compensatory increase of tyrosine hydroxylase 
activity and hypothesized that the drugs blocked catechol-
amine receptors. Arvid Carlsson’s postulation of a possible 
relationship between DA receptor blockade and antipsychotic 
effects (Carlsson 2004) shifted interest from antiserotonin 
to antidopamine effects and led to the introduction of a 
series of tests, based on the antagonism to DA agonists, eg, 
antagonism to amphetamine – induced stereotypes, in the Neuropsychiatric Disease and Treatment 2007:3(4) 498
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pharmacological screening for antipsychotic drugs (Janssen 
1998). It also provided the rationale for research that led to 
the demonstration, with the employment of receptor bindings 
assays (Seeman et al 1975), that antipsychotic drugs block 
DA receptors (Creese et al 1975).
Pharmacotherapy of schizophrenia
The introduction of CPZ focused attention on the heterogene-
ity of schizophrenia in terms of responsiveness to treatment 
(Ban 1969, 1972, 1986). Was the difference in responsiveness 
due to individual idiosyncrasies in reacting to neuroleptics, 
or to differences in the biology of the different forms of the 
disease? To answer this question Frank Fish, a British profes-
sor of psychiatry, examined the therapeutic response proﬁ  le of 
neuroleptics (Fish 1964) in different forms of schizophrenia 
using the classiﬁ  cation of Karl Leonhard, a German professor 
of psychiatry (Leonhard 1957). The signiﬁ  cant differences 
he found in responsiveness to neuroleptics between some of 
the groups could not be explained by idiosyncratic individual 
variations in responsiveness to the drugs. The differences were 
so great that in one group (affect-laden paraphrenia, one of 
the three forms of unsystematic schizophrenia in Leonhard’s 
classiﬁ  cation), more than 4 in 5 patients responded markedly 
or moderately to treatment, whereas in another group (sys-
tematic hebephrenia, one of the three categories of systematic 
schizophrenia), less than 1 responded in 4. Fish published 
his ﬁ  ndings in 1964 in Encephale, a French journal, but as a 
result of his untimely death, coupled with reservations towards 
Leonhard’s classiﬁ  cation, his ﬁ  ndings remained isolated from 
the main stream. Nevertheless, by the end of the 1960s it was 
clear that ignoring the heterogeneity of schizophrenia deprived 
neuropharmacology of the necessary feedback for developing 
clinically more selective, and thereby more effective treatments 
(Ban 1969). Furthermore, by the mid-1980s, there was suf-
ﬁ  cient evidence to conclude that resolving the heterogeneity 
of schizophrenia is an essential prerequisite for progress in the 
understanding of the biology of the different illnesses pooled 
together in the diagnostic concept of schizophrenia (Ban et al 
1986; Ban 1987, 1990).
Concluding remarks
Since the introduction of CPZ more than 50 years have 
passed; and pharmacotherapy has become the primary treat-
ment in psychiatry. The therapeutic success of CPZ was 
instrumental in the reintegration of psychiatry with the other 
medical disciplines. It turned psychiatrists from caregivers to 
full-ﬂ  edged physicians who can help their patients and not 
only listen to their problems (Lambert 1998).
Introduction of CPZ was also instrumental in the 
development of neuropsychopharmacology, a new discipline 
that provided the necessary methodology for psychiatry to 
examine and change its theoretical framework. By the end 
of the 20th century, Wilhelm Griesinger’s contention that 
mental illness is a symptom of brain disease (Griesinger 
1845) has become an accepted reality, and Joseph Moreau de 
Tours’ vision of understanding mental pathology by studying 
the effect of centrally acting drugs (Moreau de Tours 1845) 
an accepted methodology in psychiatry. But in spite of all 
the progress made in the understanding of signal transduction 
in the brain, and designing drugs which ﬁ  t like keys in their 
locks, none of the newer antipsychotic drugs has surpassed 
the effectiveness of CPZ (Ban 2004; Lieberman et al 2005). 
Hence, if an agitated and aggressive psychotic patient in 
the emergency fails to respond to some of the excellent new 
medications which may offer distinct advantages in terms 
of one or another side effect, one should not hesitate in 
prescribing good old CPZ that has remained even after 50 
years one of the most reliable antipsychotic drugs.
This manuscript is based on the author’s concluding 
remarks presented at the synthesium on 50 Years Chlor-
promazine, at the 24th CINP congress, held in Paris, France, 
in 2004.
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